Clinical Trial Update: Atezolizumab Plus Bevacizumab in First Line NSCLC Patients [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 trial evaluating the combination of Atezolizumab and Bevacizumab as first-line therapy for Non-Small Cell Lung Cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (Tecentriq) (atezolizumab)
• Bevacizumab (Avastin) (bevacizumab)

Snippet

Sponsor: Fundación GECP | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-12-04